Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports
作者： Puyuan Xing , Junling Li , Yuankai Shi , Xiangru Zhang
关键词:
摘要: Background Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis (LM) treatment recent years. Methods This paper reports two cases with exon-EGFR19 mutation. LM occurred during gefitinib an extracranial condition under control. Later, erlotinib was adopted a recurrent response. Results The progression free survival both patients over six months and their control for half nine months, respectively. may be sensitive on different levels to EGFR-TKIs. Conclusion Erlotinib can used replace if intracranial tumor progress occurs treatment. However, our conclusion still needs proven by further clinical research.
sci-hub.se 参考文章(19)
Sophie Taillibert, Florence Laigle-Donadey, Catherine Chodkiewicz, Marc Sanson, Khê Hoang-Xuan, Jean-Yves Delattre, None, Leptomeningeal metastases from solid malignancy: a review. Journal of Neuro-oncology. ,vol. 75, pp. 85- 99 ,(2005) , 10.1007/S11060-004-8101-X
Tatsuro Fukuhara, Yasuo Saijo, Tomohiro Sakakibara, Akira Inoue, Naoto Morikawa, Masayuki Kanamori, Ichiro Nakashima, Toshihiro Nukiwa, Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene Tohoku Journal of Experimental Medicine. ,vol. 214, pp. 359- 363 ,(2008) , 10.1620/TJEM.214.359
Giovanni Luca Ceresoli, Michele Reni, Giuseppe Chiesa, Angelo Carretta, Stefano Schipani, Paolo Passoni, Angelo Bolognesi, Piero Zannini, Eugenio Villa, Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer. ,vol. 95, pp. 605- 612 ,(2002) , 10.1002/CNCR.10687
Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Yasuhiro Tsuchido, Chiyuki Okuda, Young Hak Kim, Yasuaki Ikemi, Yuichi Sakamori, Tadashi Mio, Toshiya Katsura, Michiaki Mishima, Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation Cancer Chemotherapy and Pharmacology. ,vol. 68, pp. 1089- 1092 ,(2011) , 10.1007/S00280-011-1691-Z
Takeshi Masuda, Noboru Hattori, Akinobu Hamada, Hiroshi Iwamoto, Shinichiro Ohshimo, Masashi Kanehara, Nobuhisa Ishikawa, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, Nobuoki Kohno, Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemotherapy and Pharmacology. ,vol. 67, pp. 1465- 1469 ,(2011) , 10.1007/S00280-011-1555-6
Chi Wu, Yun Long Li, Zhao Meng Wang, Zhang Li, Tong Xiao Zhang, Zhong Wei, Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. ,vol. 57, pp. 359- 364 ,(2007) , 10.1016/J.LUNGCAN.2007.03.011
Tatsuya Katayama, Junichi Shimizu, Kenichi Suda, Ryoichi Onozato, Takayuki Fukui, Simon Ito, Shunzo Hatooka, Taijiro Sueda, Toyoaki Hida, Yasushi Yatabe, Tetsuya Mitsudomi, Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib Journal of Thoracic Oncology. ,vol. 4, pp. 1415- 1419 ,(2009) , 10.1097/JTO.0B013E3181B62572
Hyeon Gyu Yi, Hye Jin Kim, Yu Jung Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Chul Soo Kim, Dae Seog Heo, Yung-Jue Bang, None, Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI Lung Cancer. ,vol. 65, pp. 80- 84 ,(2009) , 10.1016/J.LUNGCAN.2008.10.016
Jeong-Eun Kim, Dae Ho Lee, Yunsuk Choi, Dok Hyun Yoon, Sang-We Kim, Cheolwon Suh, Jung-Shin Lee, Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis Lung Cancer. ,vol. 65, pp. 351- 354 ,(2009) , 10.1016/J.LUNGCAN.2008.12.011
Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Tomohiro Terada, Shiro Fujita, Kaoru Irisa, Yuichi Sakamori, Young Hak Kim, Tadashi Mio, Ken-ichi Inui, Michiaki Mishima, Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 5, pp. 950- 955 ,(2010) , 10.1097/JTO.0B013E3181E2138B